Evogene Ltd Ord (EVGN) Stock Price, Quote & News

Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 931 1900

Fax: 972 8 946 6724

Website: www.evogene.com

Address:

13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel

STOCKSGambino Mar. 16 at 2:32 PM

$EVGN ''Biomica anticipates distributing the majority of its remaining cash to its shareholders, including Evogene.''

0 · Reply

STOCKSGambino Mar. 13 at 5:00 PM

$EVGN https://x.com/StocksGambino/status/2032501573834703167

0 · Reply

STOCKSGambino Mar. 13 at 4:11 PM

$EVGN https://x.com/StocksGambino/status/2032489387854827909

0 · Reply

STOCKSGambino Mar. 13 at 3:02 PM

$EVGN

0 · Reply

STOCKSGambino Mar. 13 at 2:59 PM

$EVGN good dip opp at 5min 200ma right now if you want to add for swing

0 · Reply

STOCKSGambino Mar. 13 at 2:06 AM

$EVGN https://x.com/StocksGambino/status/2032275775575978361

0 · Reply

STOCKSGambino Mar. 12 at 10:15 PM

$EVGN https://x.com/StocksGambino/status/2032217873683538041

0 · Reply

STOCKSGambino Mar. 12 at 10:01 PM

$EVGN Feb 25, 2026 - Evogene CEO Letter Updates on Strategic Focus on ChemPass AI™ and Core Markets; - Two market focus: human health (small-molecule therapeutics via partnerships) + agriculture (ag-chemicals via AgPlenus subsidiary) Mar 09, 2026 - Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring; - Oral presentation titled "Drug Discovery and Development: Evogene" scheduled for March 24, 2026, 15:30–15:45 WET. Evogene Ltd. will present its pharma discovery achievements at the BIO-Europe Spring 2026 conference in Lisbon.

0 · Reply

STOCKSGambino Mar. 12 at 7:10 PM

$EVGN https://x.com/StocksGambino/status/2032169775938617525

0 · Reply

STOCKSGambino Mar. 12 at 4:18 PM

$EVGN https://x.com/StocksGambino/status/2032112428834504950

0 · Reply

Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline

2026-03-13T23:50:52.000Z - 2 days ago

Q4 2025 Evogene Ltd Earnings Call Transcript

Mon, 09 Mar 2026 09:00:00 -0400 - 7 days ago

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Thu, 05 Mar 2026 16:46:09 -0500 - 10 days ago

Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript

2026-03-05T12:41:07.000Z - 11 days ago

Evogene (EVGN) Focuses on Key Markets Following Strategic Shift

2026-03-05T12:10:35.000Z - 11 days ago

Evogene Earnings Review: Q4 Summary

Thu, 05 Mar 2026 07:00:00 -0500 - 11 days ago

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

2026-03-04T19:01:57.000Z - 11 days ago

An Overview of Evogene's Earnings

Wed, 25 Feb 2026 08:00:00 -0500 - 19 days ago

Evogene Releases CEO Letter to Shareholders

Thu, 19 Feb 2026 08:00:00 -0500 - 25 days ago

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

2026-02-17T13:33:51.000Z - 27 days ago

Evogene (EVGN) Partners with QUT to Combat Lung Cancer Drug Resistance

Tue, 17 Feb 2026 08:00:00 -0500 - 27 days ago

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Wed, 11 Feb 2026 08:00:00 -0500 - 4 weeks ago

Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

Tue, 10 Feb 2026 13:20:00 -0500 - 4 weeks ago

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

2026-02-10T13:29:55.000Z - 4 weeks ago

Evogene (EVGN) Expands Collaboration with Google Cloud to Boost AI Capabilities

Tue, 10 Feb 2026 08:00:00 -0500 - 4 weeks ago

Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

Mon, 09 Feb 2026 08:00:00 -0500 - 5 weeks ago

Evogene Appoints Prof. John Irwin and Prof.

2026-02-05T11:26:12.000Z - 5 weeks ago

Evogene (EVGN) Subsidiary Biomica Secures Licensing Deal for Innovative Cancer Therapy

Wed, 04 Feb 2026 22:00:00 -0500 - 5 weeks ago

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

2026-02-04T13:41:08.000Z - 5 weeks ago

Evogene (EVGN) Signs Licensing Agreement for Promising Cancer Therapy

2026-01-07T12:30:48.000Z - 2 months ago

Evogene (EVGN) and Unravel Biosciences Partner to Tackle Neurological Diseases

Wed, 07 Jan 2026 07:00:00 -0500 - 2 months ago

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Tue, 30 Dec 2025 07:00:00 -0500 - 2 months ago

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

Thu, 11 Dec 2025 18:22:48 -0500 - 3 months ago

EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Fri, 21 Nov 2025 12:13:24 -0500 - 4 months ago

EverGen Infrastructure Corp. (EVGN:CA) Q3 2025 Earnings Call Transcript

Thu, 20 Nov 2025 12:13:26 -0500 - 4 months ago

Evogene Ltd. (EVGN) Q3 2025 Earnings Call Transcript

Thu, 20 Nov 2025 07:00:00 -0500 - 4 months ago

Evogene Reports Third Quarter 2025 Financial Results

2025-11-19T16:03:33.000Z - 4 months ago

What's Next: Evogene's Earnings Preview

Tue, 11 Nov 2025 07:00:00 -0500 - 4 months ago

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Thu, 06 Nov 2025 09:00:00 -0500 - 4 months ago

Evogene Schedules Third Quarter 2025 Financial Results Release

Thu, 28 Aug 2025 07:00:00 -0400 - 7 months ago

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Tue, 19 Aug 2025 13:31:58 -0400 - 7 months ago

Evogene Ltd. (EVGN) Q2 2025 Earnings Call Transcript

Tue, 19 Aug 2025 07:00:00 -0400 - 7 months ago

Evogene Reports Second Quarter 2025 Financial Results

2025-08-18T15:02:56.000Z - 7 months ago

Preview: Evogene's Earnings

Tue, 12 Aug 2025 07:00:00 -0400 - 7 months ago

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Tue, 29 Jul 2025 07:00:00 -0400 - 8 months ago

Evogene Schedules Second Quarter 2025 Financial Results Release

Tue, 08 Jul 2025 07:00:00 -0400 - 8 months ago

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

Tue, 10 Jun 2025 07:00:00 -0400 - 9 months ago

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

Wed, 21 May 2025 14:08:24 -0400 - 10 months ago

Evogene Ltd. (EVGN) Q1 2025 Earnings Call Transcript

Wed, 21 May 2025 07:00:00 -0400 - 10 months ago

Evogene Reports First Quarter 2025 Financial Results

2025-05-20T15:02:35.000Z - 10 months ago

Insights into Evogene's Upcoming Earnings

Thu, 08 May 2025 07:00:00 -0400 - 11 months ago

Evogene Schedules First Quarter 2025 Financial Results Release

Mon, 21 Apr 2025 07:00:00 -0400 - 11 months ago

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Thu, 06 Mar 2025 12:48:23 -0500 - 1 year ago

Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:15 AM EST - 1 year ago

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 7:00 AM EST - 1 year ago

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

Evogene Schedules Fourth Quarter 2024 Financial Results Release

Feb 13, 2025, 8:00 AM EST - 1 year ago

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Thu, 21 Nov 2024 13:46:50 -0500 - 1 year ago

Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript

Nov 21, 2024, 7:30 AM EST - 1 year ago

Evogene Reports Third Quarter 2024 Financial Results

Nov 19, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Nov 12, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Nov 7, 2024, 7:00 AM EST - 1 year ago

Evogene Schedules Third Quarter 2024 Financial Results Release

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Aug 23, 2024, 8:55 AM EDT - 1 year ago

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Aug 22, 2024, 5:42 PM EDT - 1 year ago

Evogene Ltd. (EVGN) Q2 2024 Earnings Call Transcript

Aug 22, 2024, 7:00 AM EDT - 1 year ago

Evogene Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 7:11 AM EDT - 1 year ago

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Evogene Schedules Second Quarter 2024 Financial Results Release

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil

STOCKSGambino Mar. 16 at 2:32 PM

$EVGN ''Biomica anticipates distributing the majority of its remaining cash to its shareholders, including Evogene.''

0 · Reply

STOCKSGambino Mar. 13 at 5:00 PM

$EVGN https://x.com/StocksGambino/status/2032501573834703167

0 · Reply

STOCKSGambino Mar. 13 at 4:11 PM

$EVGN https://x.com/StocksGambino/status/2032489387854827909

0 · Reply

STOCKSGambino Mar. 13 at 3:02 PM

$EVGN

0 · Reply

STOCKSGambino Mar. 13 at 2:59 PM

$EVGN good dip opp at 5min 200ma right now if you want to add for swing

0 · Reply

STOCKSGambino Mar. 13 at 2:06 AM

$EVGN https://x.com/StocksGambino/status/2032275775575978361

0 · Reply

STOCKSGambino Mar. 12 at 10:15 PM

$EVGN https://x.com/StocksGambino/status/2032217873683538041

0 · Reply

STOCKSGambino Mar. 12 at 10:01 PM

0 · Reply

STOCKSGambino Mar. 12 at 7:10 PM

$EVGN https://x.com/StocksGambino/status/2032169775938617525

0 · Reply

STOCKSGambino Mar. 12 at 4:18 PM

$EVGN https://x.com/StocksGambino/status/2032112428834504950

0 · Reply

STOCKSGambino Mar. 12 at 3:37 PM

$EVGN https://x.com/StocksGambino/status/2032106724656632304

0 · Reply

STOCKSGambino Mar. 12 at 3:04 PM

$EVGN https://x.com/StocksGambino/status/2032105005381992890

0 · Reply

STOCKSGambino Mar. 12 at 2:51 PM

$EVGN https://x.com/StocksGambino/status/2032102602377244757

0 · Reply

omenkes Mar. 11 at 6:55 PM

$EVGN @opgntozero You might have seen me here before. I am and have been bullish on the science of the company, but not so much on mr Haviv. this company has very valuable pieces to it (for example finally foods stake is going to be worth a lot). agplenus is a part less discussed here, but its probably worth a lsarge multiple of this company if it had 100M shares outstading. why? agplenus was the 5+ years pilot of chempass and it has stakes in three different new moa herbicides that are in advanced stages with corteva & bayer. their exact development stage is undisclosed, but: compare this 2022 presentation www.evogene.com/wp-content/uploads/2022/04/AgPlenus-company-presenation_April-2022_FINAL.pdf at page 17 to this 2025 one: https://evogene.com/wp-content/uploads/2025/03/AgPlenus_company_presentation_Mar_2025_FINAL.pdf at page 30. we are a year further in development and at least the bayer one should be getting closer to pre commercial. https://agplenus.com/agplenus-announces-licensing-collaboration-agreement-with-bayer-to-develop-a-new-sustainable-weed-control-solution/ was the 2024 announcement of the licensing. lavie bio had issues and corteva pulled out. this one is much better.

0 · Reply

opgntozero Mar. 5 at 4:23 PM

$EVGN this junk will go to ZERO!!! Ofer Haviv is telling every year a new story not 1 insider buying think about it next reverse splitt a new stock offering will come soon Ofer Haviv!

0 · Reply

Bettt Mar. 5 at 4:16 PM

$EVGN this heading for another R/S?

0 · Reply

DJTHollaAtMe Feb. 27 at 2:48 PM

$EVGN Adding heavily here - MC is way too low relative to the industry they are penetrating.

0 · Reply

SuperBusa Feb. 25 at 7:47 PM

$EVGN

0 · Reply

6GodEnergy Feb. 23 at 5:39 PM

.@SqueezeSharkie moving different. .Ice-cold vision, pure substance. Costs you nothing but a tap, follow him now!! $TOVX $SPRB $IPHA $EVGN *^

0 · Reply

OfficialStocktwitsUser Feb. 21 at 10:11 AM

$EVGN RSI: 30.61, MACD: -0.0435 Vol: 0.07, MA20: 1.01, MA50: 1.04 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

GPDL Feb. 21 at 5:17 AM

$EVGN Market cap is messed up for the company value on a sale, all is worth about 30-40 million, bad management, huge upside one day

0 · Reply

cowboygold Feb. 20 at 6:25 PM

$EVGN what a joke. Unreal. Total waste of time and money. We should hire a lawyer and fuck these greedy bums

0 · Reply

Market Cap	4.28M
Revenue (ttm)	3.85M
Net Income (ttm)	-8.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-220.52%
Debt to Equity Ratio	0.00

Volume	60,223
Avg Vol	548,738
Day's Range	N/A - N/A
Shares Out	5.37M
Stochastic %K	52%
Beta	1.36
Analysts	Strong Buy
Price Target	$2.50